A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs JNJ 37822681 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01812642).
- 28 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.